Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne,
NY 10532
Telefone: 914-347-4300
Fax: 914-347-4560
Web Site: http://www.acorda.com
| Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The companys lead product candidate is Fampridine-SR, which completed two positive Phase III clinical trials for the improvement of walking ability in patients with MS. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York. |
|
| Principais estatísticas | Mais da Reuters
Descrição expandida da empresa |
| |
| | Pago | Exercido | Dr. Ron Cohen M.D., 54
Founder, Chairman, Chief Exec. Officer and Pres |
$
668.00K |
$
3.39M | Mr. David Lawrence M.B.A., 54
Chief Financial Officer and Principal Accounting Officer |
N/D
| N/D | Ms. Jane Wasman J.D., 54
Exec. VP, Gen. Counsel and Corp. Sec. |
N/D
| N/D | Dr. Andrew R. Blight Ph.D., 59
Chief Scientific Officer |
N/D
| N/D | Dr. Thomas C. Wessel M.D, Ph.D., 54
Chief Medical Officer |
N/D
| N/D |
|
|
|
Somas desde
31-Dec-08
e valores de compensação são para o ano fiscal que termina nesta data. "Pago" é salário, bônus, etc. "Exercício" é o valor de ações exercidas durante o ano fiscal.
| |
|
Ajuda
0.07 (0.23%) 
Perfil
A Reuters oferece mais 
